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ORIGINAL ARTICLE
The clinical association of programmed 
cell death protein 4 (PDCD4) with solid tumors 
and its prognostic significance: a meta-analysis
John Zeng Hong Li1†, Wei Gao1†, Wai‑Kuen Ho1, Wen Bin Lei2, William Ignace Wei1, Jimmy Yu‑Wai Chan1 
and Thian‑Sze Wong1*
Abstract 
Background: Programmed cell death protein 4 (PDCD4) is a novel tumor suppressor protein involved in pro‑
grammed cell death. Its association with cancer progression has been observed in multiple tumor models, but 
evidence supporting its association with solid tumors in humans remains controversial. This study aimed to determine 
the clinical significance and prognostic value of PDCD4 in solid tumors.
Methods: A systematic literature review was performed to retrieve publications with available clinical informa‑
tion and survival data. The eligibility of the selected articles was based on the criteria of the Dutch Cochrane Centre 
proposed by the Meta‑analysis Of Observational Studies in Epidemiology group. Pooled odds ratios (ORs), hazard 
ratios (HRs), and 95% confidence intervals (CIs) for survival analysis were calculated. Publication bias was examined by 
Begg’s and Egger’s tests.
Results: Clinical data of 2227 cancer patients with solid tumors from 23 studies were evaluated. PDCD4 expression 
was significantly associated with the differentiation status of head and neck cancer (OR 4.25, 95% CI 1.87–9.66) and 
digestive system cancer (OR 2.87, 95% CI 1.84–4.48). Down‑regulation of PDCD4 was significantly associated with 
short overall survival of patients with head and neck (HR: 3.44, 95% CI 2.38–4.98), breast (HR: 1.86, 95% CI 1.36–2.54), 
digestive system (HR: 2.12, 95% CI 1.75–2.56), and urinary system cancers (HR: 3.16, 95% CI 1.06–9.41).
Conclusions: The current evidence suggests that PDCD4 down‑regulation is involved in the progression of several 
types of solid tumor and is a potential marker for solid tumor prognoses. Its clinical usefulness should be confirmed 
by large‑scale prospective studies.
Keywords: Programmed cell death protein 4 (PDCD4), Solid tumor, Meta‑analysis, Prognosis, Overall survival, 
Disease‑free survival, Recurrence‑free survival
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Background
Programmed cell death protein 4 (PDCD4) is a novel 
tumor suppressor protein involved in programmed 
cell death. The PDCD4 gene is located on chromosome 
10q24, and its allelic loss/gain is frequently reported in 
human cancers. Up-regulation of PDCD4 is observed 
after the initiation of apoptosis, suggesting that loss of, 
or reduced, PDCD4 expression could contribute to the 
anti-apoptotic property of cancer cells [1]. In mouse 
epidermal JB6 cells, which are resistant to anchorage-
dependent cell death and neoplastic transformation, 
high levels of PDCD4 expression could be induced in 
response to the presence of tumor promoters such as 
12-O-tetradecanoylphorbol-13-acetate [2] and tumor 
necrosis factor-alpha [3]. Therefore, it has been suggested 
that PDCD4 is a potent tumor suppressor gene. PDCD4 
could inhibit neoplastic transformation through inhibi-
tion of adaptor protein-1 (AP-1) activation [3]. Structur-
ally, PDCD4 could interact with RNA helicase eukaryotic 
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translation initiation factor 4A (eIF4A), inhibiting its 
helicase activity and affecting protein translation [4, 5]. 
In addition, PDCD4 could inhibit nuclear factor kappaB 
(NF-κB)-dependent transcription and related pathways 
[6].
Loss of important tumor suppressors with critical func-
tions during the transformation process is a hallmark 
of cancer. Identifying key tumor suppressor proteins is 
important for the sub-classification of tumors at different 
stages with different behaviors. Moreover, the elucidation 
of the pathways associated with tumor suppressors could 
help identify predictive markers for prognostic use and 
provide novel insights into cancer treatment. Accumu-
lated results in preclinical studies indicate that PDCD4 is 
a novel tumor suppressor gene with anti-neoplastic prop-
erties [7–9]. Nevertheless, some studies have suggested 
the conflicting conclusion that PDCD4 does not exert a 
tumor-suppressing effect in certain malignancies, such as 
non-small cell lung cancer [10, 11]. To explore whether 
PDCD4 consistently acts as a tumor suppressor and posi-
tive prognostic marker for solid tumors, we conducted 
an updated meta-analysis to evaluate the clinical signifi-
cance and prognostic value of PDCD4 in human cancers.
Methods
Literature search
A systematic literature search through PubMed, 
EMBASE, and MEDLINE was performed using the fol-
lowing main keywords: “PDCD4” and “cancer” or “car-
cinoma” or “tumor” or “malignancy.” All studies that 
examined the expression status of PDCD4 were recruited 
regardless of the detection methods used. The last search 
was performed on January 12th, 2016.
Study selection
Two reviewers (JZHL and WG) manually screened and 
selected the eligible studies independently. Studies that 
were not reported in English or Chinese, review articles, 
studies that had used cell lines and animal models with-
out any data on human tissue samples, and studies with-
out sufficient data for calculation were excluded from the 
analysis.
Methodology quality assessment
The studies on prognosis were evaluated using the cri-
teria of the Dutch Cochrane Centre proposed by Meta-
analysis Of Observational Studies in Epidemiology 
(MOOSE) group [12]. The following inclusion criteria 
were used: (1) trial dealt with PDCD4; (2) clear definition 
of study design; (3) clear definition of outcome assess-
ment, including overall survival (OS), disease-specific 
survival (DSS), disease-free survival (DFS), and relapse-
free survival (RFS); (4) clear definition of cut-off score 
of PDCD4 expression or high/low evaluation; and (5) a 
follow-up period of at least 12 months.
Data extraction
The selected publications were accessed by two review-
ers (JZHL and WG). The following details were retrieved 
from the selected papers: (1) general information, includ-
ing the first author, publication year, case populations, 
cancer types, sample types, and test methods; (2) the case 
number in each of the sub-groups with different PDCD4 
expression levels and diverse clinicopathologic proper-
ties; and (3) the results of survival analysis, including haz-
ard ratios (HRs) and 95% confidence intervals (CIs).
Statistical analysis
Pooled odd ratios (ORs), HRs, and 95% CIs were calcu-
lated for the evaluation of the clinicopathologic associa-
tion of PDCD4 and its prognostic value in solid tumors. 
To check whether there was homogeneity among the 
individual ORs/HRs for the selection of the optimal 
effects model analysis, a heterogeneity test with the 
inconsistency index (I2) statistic and Q statistic (P value) 
was performed. Substantial heterogeneity was indicated 
when I2 ≥ 50% and P < 0.05, and a random effects model 
was adopted; a fixed effects model was appropriate when 
I2  <  50% and P  >  0.05. After a suitable model had been 
chosen, Forest plots with pooled OR/HR and 95% CIs 
were then retrieved from the individual HRs and 95% 
CIs. Pooled OR/HR  >  1 suggested that the worst prog-
noses were more likely to occur in the patients with no, 
or low levels of, PDCD4 expression than those with high 
levels of PDCD4 expression. Statistically significant dif-
ferences between groups with diverse PDCD4 expression 
levels was determined if the 95% CI did not overlap 1. 
In addition to the calculation of overall OR/HR and 95% 
CI, subgroup analysis was performed with respect to the 
case population (Asian/European/North American), can-
cer type (brain tumor/head and neck cancer/breast can-
cer/digestive system cancer/respiratory system tumor/
gynecologic tumor/urinary system cancer), and sample 
type (protein/RNA).
Publication bias was assessed by the Begg’s and Egger’s 
tests [13]. P  <  0.05 represented a statistically significant 
publication bias. All analyses were performed with Stata 
software version 12.0 (Stata Corporation, College Station, 
TX, USA).
Results
Study characteristics and qualitative assessment
According to the selection criteria, 493 articles were 
found in the initial screening. After removing 445 irrel-
evant articles, 33 articles were selected for further evalu-
ation. According to the critical checklist of the Dutch 
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Cochrane Centre, 23 articles fulfilled all of the quality 
assessment criteria. These 23 articles, involving a total of 
2227 solid tumor cases, were included in the meta-analy-
sis. Figure 1 shows the selection process. The characteris-
tics of the included studies are shown in Table 1.
Associations of PDCD4 down‑regulation with the 
clinicopathologic parameters of cancer patients
The associations between PDCD4 expression and the 
clinicopathologic features of patients with solid tumors 
are shown in Table  2. Four studies of digestive system 
cancers [7, 14–16] and one study of urinary system can-
cers [17] examined associations between tumor size and 
PDCD4 expression level. All of the studies were carried 
out on Asian patients using antigen-based methods, 
and the combined OR indicated no significant associa-
tion. Low PDCD4 expression level was associated with 
advanced T category of urinary system cancers (OR 4.87, 
95% CI 1.69–14.00) [17] and head and neck cancers (OR 
2.15, 95% CI 1.10–4.19) [18]. However, PDCD4 expres-
sion level was not associated with the T category of 
digestive system cancers (OR 0.98, 95% CI 0.46–2.08) [15, 
19]. There was no obvious evidence for an association 
between PDCD4 expression and the N category of head 
and neck cancers [20, 21], respiratory system cancers 
[22], and digestive system cancers [7, 15, 19, 23]. Low 
PDCD4 level was associated with advanced M category 
of urinary system cancers (OR 4.87, 95% CI 1.69–14.00) 
[17] and advanced clinical stage of head and neck cancers 
(OR 2.30, 95% CI 1.44–3.69) [18, 20, 21, 24].
Low PDCD4 expression was significantly associated 
with advanced stages of head and neck cancers (Fig. 2a). 
Low PDCD4 level was associated with moderately/poorly 
differentiated head and neck cancers (OR 4.25, 95% CI 
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1.87–9.66) [20, 21] and digestive system cancers (OR 
2.87, 95% CI 1.84–4.48) [15, 23, 25–27] (Fig. 3a). No pub-
lication bias was observed (Figs. 2b, 3b).
Quantitative analysis of the association between PDCD4 
expression and OS
Combined analysis of the 20 studies in 10 papers that 
addressed OS [7, 15, 17, 18, 24, 28–32] showed that 
reduced PDCD4 expression had an unfavorable impact 
on the OS of patients with solid tumors (HR: 2.24, 95% 
CI 1.93–2.60) (Table  3). Significant associations were 
observed in the univariate model (HR: 2.05, 95% CI 1.69–
2.49) and multivariate model (HR: 2.52, 95% CI 2.01–
3.16) (Fig. 4a). Subgroup analysis of different tumor types 
(Table 3) showed that reduced PDCD4 expression had an 
unfavorable impact on the OS of patients with head and 
neck cancers (HR: 3.24, 95% CI 1.93–5.45) [18, 24, 29], 
breast cancers (HR: 1.86, 95% CI 1.36–2.54) [30], diges-
tive system cancers (HR: 2.12, 95% CI 1.75–2.56) [7, 15, 
28, 31, 32], and urinary system cancers (HR: 3.16, 95% CI 
1.06–9.41) [17]. No evidence of significant publication 
bias was observed with Begg’s test (P = 0.940) and Egg-
er’s test (P = 0.744) (Fig. 4b).
Quantitative analysis of the association between PDCD4 
expression and DSS
In total, 4 studies that addressed DSS were pooled for 
analysis [24, 28, 33, 34]. The pooled HR showed sig-
nificant differences in DSS between the high and low 
PDCD4 expression groups (HR: 3.59, 95% CI 1.23–10.50) 
(Fig.  5a). Down-regulation of PDCD4 expression was 
associated with unsatisfactory DSS in patients with head 
and neck cancers (HR: 5.05, 95% CI 1.12–62.50) [24], 
brain tumors (HR: 15.87, 95% CI 3.62–71.43) [33], and 
gynecologic cancers (HR: 3.36, 95% CI 1.43–7.81) [34]. 
For digestive system cancers, no association was dem-
onstrated (HR: 1.31, 95% CI 1.00–1.72) [28]. An asso-
ciation between low PDCD4 expression and short DSS 
was found in patients from Asia (HR: 5.67, 95% CI 2.13–
5.12) but not in patients from Europe (HR: 1.31, 95% 
Table 2 Associations between  PDCD4 down-regulation and  the clinicopathologic parameters of  patients with  solid 
tumors
OR odds ratio, CI confidence interval, NA not available
a The data of PDCD4 expression are expressed as the number of cases in the former subgroup versus the number of cases in the latter subgroup, e.g., the number of 
cases in the large tumor subgroup versus the number of cases in the small tumor subgroup
Parameter Study subjects Reference(s) Total cases PDCD4 expression 
(cases)a
OR 95% CI I2 (%) P
Negative Positive
Tumor size (large vs. small) Tumor type
 Digestive system cancer [7, 14–16] 530 114 vs. 169 84 vs. 163 1.49 1.00–2.22 51.3 0.08
 Urinary system cancer [17] 66 6 vs. 29 5 vs. 26 1.08 0.29–3.95 NA NA
Total 596 120 vs. 198 89 vs. 189 1.45 0.99‑2.12 40.8 0.13
T category (T3 + 4 vs. T1 + 2) Tumor type
 Digestive system cancer [15, 19] 238 96 vs. 24 95 vs. 23 0.98 0.46‑2.08 25.1 0.26
 Urinary system cancer [17] 66 22 vs. 13 8 vs. 23 4.87 1.69–14.0 NA NA
 Head and neck cancer [18] 190 44 vs. 73 16 vs. 57 2.15 1.10–4.19 NA NA
Total 494 162 vs. 110 119 vs. 103 1.68 0.82–3.43 60.8 0.04
N category (N+ vs. N−) Tumor type
 Digestive system cancer [15, 19, 23] 465 164 vs. 119 91 vs. 91 1.02 0.53‑1.93 58.5 0.05
 Head and neck cancer [20, 21] 114 19 vs. 36 11 vs. 48 3.39 0.59‑19.53 55.3 0.14
 Respiratory system 
cancer
[22] 124 44 vs. 59 11 vs. 10 0.68 0.26–1.74 NA NA
Population
 Asian [15, 19–21, 23] 579 183 vs. 155 102 vs. 139 1.26 0.68–2.33 58.8 0.02
 European [22] 124 44 vs. 59 11 vs. 10 0.68 0.26–1.74 NA NA
Total 703 227 vs. 214 113 vs. 149 1.15 0.67–1.68 55.4 0.03
M category (M+ vs. M−) Tumor type
 Urinary system tumor [17] 66 22 vs. 13 8 vs. 23 4.87 1.69–14.0 NA NA
 Head and neck cancer [18] 190 10 vs. 107 4 vs. 69 1.61 0.49–5.34 NA NA
 Digestive system cancer [19, 23] 213 4 vs. 117 4 vs. 88 0.72 0.09–5.83 54 0.14
Total 469 36 vs. 237 16 vs. 180 2.51 1.20–5.26 46.2 0.10
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Fig. 2 Forest plots and funnel plots demonstrating the associations between programmed cell death protein 4 (PDCD4) expression and clini‑
cal stage of various types of cancer. a Forest plot shows that low PDCD4 expression is significantly associated with advanced stages of head and 
neck cancers. Two cancer types were reported by Ma et al.: Ma [26] (01) for gastric cancer and Ma [26] (02) for pancreatic cancer. OR odds ratio, CI 
confidence interval. b Funnel plot shows no evidence of publication bias among papers on the association between PDCD4 expression and clinical 
stage of various types of cancer
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Fig. 3 Forest plots and funnel plots demonstrating the associations between PDCD4 expression and histological differentiation of various types of 
cancer. a Forest plot shows that low PDCD4 expression is significantly associated with moderate/poor differentiation of digestive system cancers 
and head and neck cancers. Two sites of PDCD4 expression were reported by Kakimoto et al.: Kakimoto [50] (01) for PDCD4 expression in nucleus 
and Kakimoto [50] (02) for PDCD4 expression in cytoplasm of gastric cancer cells. Two sites of PDCD4 expression were reported by Nagao et al.: 
Nagao [15]  (01) for PDCD4 expression in nucleus and Nagao [15] (02) for PDCD4 expression in cytoplasm of pancreatic cancer cells. Three cancer 
types were reported by Ma et al.: Ma [26] (01) for gastric cancer, Ma [26] (02) for pancreatic cancer, and Ma [26] (03) for colorectal cancer. OR odds 
ratio, CI confidence interval. b Funnel plot shows no evidence of publication bias among papers on the association between PDCD4 expression and 
histological differentiation of various types of cancer
Page 10 of 16Li et al. Chin J Cancer  (2016) 35:95 
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Fig. 4 Forest plots and funnel plots demonstrating the associations between PDCD4 expression and overall survival (OS) of patients with solid 
tumors. a Forest plot shows that low PDCD4 expression level is significantly associated with a low OS rate. In total, 20 studies from 10 papers were 
included. Two T subcategories of gastric cancer were reported by Guo et al.: Guo [7] (01) for pT2a gastric cancer and Guo [7] (02) for pT2b gastric 
cancer. Two sites of PDCD4 expression were reported by Nagao et al.: Nagao [15] (01) for PDCD4 expression in nucleus and Nagao [15] (02) for 
PDCD4 expression in cytoplasm of pancreatic cancer cells. Different Duke’s stages were reported by Horiuchi et al.: Horiuchi [31] (01) for Duke’s 
stage B, Horiuchi [31] (02) for Duke’s stage C, and Horiuchi [31] (03) for Duke’s stage D colorectal cancer in multivariate analysis; Horiuchi [31] (04) for 
Duke’s stage B, Horiuchi [31] (05) for Duke’s stage C, and Horiuchi [31] (05) for Duke’s stage D colorectal cancer in univariate analysis. A fixed effects 
model was used to calculate the pooled hazard ratio (HR) for OS. Significant associations are observed in univariate model and in multivariate 
model. b Funnel plot shows no evidence of publication bias among papers on the association between PDCD4 expression and overall survival rate 
of various types of cancer. s.e. standard error. The P value is 0.940 in Begg’s test and is 0.744 in Egger’s test
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CI 1.00–1.72) (Table 3). The Begg’s test (P = 0.308) and 
Egger’s test (P = 0.215) showed no significant publication 
bias (Fig. 5b).
Quantitative analysis of the association between PDCD4 
expression and DFS/RFS
The pooled HR for DFS/RFS showed a significant asso-
ciation with PDCD4 down-regulation (HR: 2.01, 95% CI 
1.58–2.56) (Fig.  6a) [29–32, 35]. Low PDCD4 expres-
sion was associated with short DFS/RFS of patients with 
head and neck cancers (HR: 2.10, 95% CI 1.30–3.39) [29], 
digestive system cancers (HR: 2.57, 95% CI 1.74–3.78) 
[31, 32], and gynecologic cancers (HR: 3.42, 95% CI 1.41–
8.33) [35]; for breast cancer patients, no association was 
observed (HR: 1.23, 95% CI 0.79–1.92) [30] (Table  3). 
The Begg’s test (P = 0.902) and Egger’s test (P = 0.550) 
showed no significant publication bias (Fig. 6b).
Discussion
In this meta-analysis, we examined the association 
between PDCD4 expression and the clinicopathologic 
parameters of cancers from different anatomical sites, 
including the brain, head and neck, breast, and digestive, 
gynecologic, and urinary systems. Our results indicated 
Fig. 5 Forest plots and funnel plots demonstrating the associations between PDCD4 expression and disease‑specific survival (DSS) of patients with 
solid tumors. a Forest plot shows that low PDCD4 expression level is significantly associated with a low DSS rate. A random effects model was used 
to calculate the pooled HR for DSS. b Funnel plot shows no evidence of publication bias among papers on the association between PDCD4 expres‑
sion and disease‑specific survival rate of various types of cancer. The P value is 0.308 in Begg’s test and is 0.215 in Egger’s test
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Fig. 6 Forest plots and funnel plots demonstrating the associations between PDCD4 expression and disease‑free survival (DFS)/relapse‑free 
survival (RFS) of patients with solid tumors. a Forest plot shows that low PDCD4 expression level is significantly associated with a low DFS/RFS 
rate. In total, 10 studies in 5 papers were included. A fixed effects model was used to calculate the pooled HR for DFS/RFS. Significant associations 
are observed in univariate model and in multivariate model. Different Duke’s stages were reported by Horiuchi et al.: Horiuchi [31] (01) for Duke’s 
stage B and Horiuchi [31] (02) for Duke’s stage C colorectal cancer in multivariate analysis; Horiuchi [31] (04) for Duke’s stage B and Horiuchi [31] (05) 
for Duke’s stage C colorectal cancer in univariate analysis. b Funnel plot shows no evidence of publication bias among papers on the association 
between PDCD4 expression and disease‑free survival rate of various types of cancer. The P value is 0.902 in Begg’s test and is 0.550 in Egger’s test
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a strong negative association of PDCD4 expression with 
tumor size and differentiation status of solid tumors. In a 
stratified analysis, reduced PDCD4 expression level was 
associated with late T subcategories in head and neck 
tumors and urinary system cancers as well as distant 
metastasis of urinary system cancers. Furthermore, low 
PDCD4 expression was associated with advanced stage 
head and neck cancers and respiratory system cancers.
Epithelial differentiation was a determining factor 
in the prognoses of head and neck cancers. Poorly dif-
ferentiated cancers were highly proliferative compared 
with their highly differentiated counterparts. In addi-
tion, differentiation status was important in maintain-
ing a tumorigenic and treatment-resistant cancer stem 
cell subpopulation in head and neck cancers [36]. Hence, 
cancer treatment with differentiation inducers (such 
as retinoic acid) could inhibit cancer cell proliferation 
and is known as differentiation cancer therapy [37, 38]. 
In head and neck cancers, it had been demonstrated 
that valproic acid or all-trans retinoic acid could inhibit 
the growth of head and neck squamous cell carcinomas 
by inducing terminal differentiation [39]. Furthermore, 
differentiation therapy could help in suppressing and 
eradicating the cancer stem cell population in head and 
neck squamous cell carcinomas [36, 40]. The association 
between PDCD4 expression and cancer cell differentia-
tion was clearly demonstrated in peripheral blood can-
cers. PDCD4 expression was induced in NB4 and HL-60 
acute myelocytic leukemia (AML) cell lines, primary 
human promyelocytic leukemia (AML-M3) cells, and 
CD34+ hematopoietic progenitor cells in the presence 
of all-trans retinoic acid. Differentiation induction could 
be prevented if PDCD4 was silenced using small interfer-
ing RNA (siRNA) [41]. In solid tumors, PDCD4 expres-
sion was inhibited by the phosphatidylinositol 3-kinase 
(PI3K)/protein kinase B (PKB/AKT)/mammalian target 
of rapamycin (mTOR) pathway. During adipogenic dif-
ferentiation of adipose tissue-derived mesenchymal stem 
cells, PDCD4 expression was reduced and AKT phos-
phorylation was increased in a time-dependent manner 
[42]. Because of the association between PDCD4 and 
cancer differentiation, PDCD4 restoration could be a 
novel approach for differentiation cancer therapy, result-
ing in effective suppression of solid tumor development 
and further improving the prognosis [43].
In urinary system cancer, PDCD4 suppression was 
associated with the metastatic status of the patients [17]. 
PDCD4-knockout mice developed spontaneous lym-
phomas with systematic dissemination and frequent 
liver/renal metastasis [44]. Preclinical studies have indi-
cated that PDCD4 could control key genes involved 
in cancer migration and metastasis [25, 45, 46]. The 
expression of urokinase plasminogen activator surface 
receptor (u-PAR), which mediates plasmin-mediated 
extracellular matrix degradation, was shown to be con-
trolled by PDCD4 [45]. In PDCD4-knockdown cancer 
cells, epithelial cadherin 1 (E-cadherin) promoter activ-
ity was inhibited. In contrast, in colorectal cancer cells 
overexpressing PDCD4, E-cadherin protein level was 
increased accordingly [25]. In ACHN and 786-O renal 
cancer cells, PDCD4 regulated AKT phosphorylation, 
leading to the migration or invasion of cancer cells via 
the up-regulation of the mammalian target of rapamycin 
complex 1 (mTORC1) [46]. Metastasis of cancer cells is 
a main cause of death in laryngeal carcinoma patients. 
Moreover, molecular factors involved in metastasis, espe-
cially in the epithelial-mesenchymal transition (EMT), 
could be a possible mechanism of cancer cell resistance. 
Because low PDCD4 expression was significantly associ-
ated with metastasis in urinary system cancers, PDCD4 
could be a novel target for improving the prognosis of 
this malignancy.
Several limitations were observed in this meta-anal-
ysis. A small sample size was observed in one cancer 
group. Moreover, multiple cut-off criteria, discrepan-
cies among diverse tumor properties, and the therapy 
received also affected the results. In most of the stud-
ies included in prognostic assessment, all clinical stages 
were represented in the respective cancer cases. How-
ever, the study reported by Dou et al. [32], only focused 
on advanced stage rectal cancer, and the low PDCD4 
expression within these patients was not significantly 
associated with the 5-year OS or DFS indicated by the 
95% CI overlapping 1. Furthermore, the subcellular 
localization of the PDCD4 protein affects cancer behav-
ior. During tumor progression, PDCD4 protein translo-
cation from the nucleus to the cytoplasm was observed 
in cancer cells [47, 48]. Accumulation of cytoplasmic 
PDCD4 protein is reported in both normal and can-
cer cell lines [49]. Almost all of the studies included 
in our meta-analysis measured the total PDCD4 pro-
tein level in the tissue samples rather than the sepa-
rate nuclear or cytoplasmic PDCD4 protein level. In 
the study conducted by Nagao et  al. [15], both nuclear 
and cytoplasmic PDCD4 protein pools were examined 
in pancreatic cancer patients. Different ORs and 95% 
CIs were obtained for the assessment of clinical stage 
and OS. A similar situation was observed in the study 
by Kakimoto et  al. [50] that examined the association 
between PDCD4 expression and histological differen-
tiation. These findings suggest that the prognostic value 
of PDCD4 in human malignancies should be studied by 
further stratified analysis, including the determination of 
precise cellular localization of PDCD4.
Page 15 of 16Li et al. Chin J Cancer  (2016) 35:95 
Conclusions
Our results demonstrated that reduced expression of 
PDCD4 in solid tumors is an unfavorable prognostic 
indicator. We noticed that the sample size for a particu-
lar cancer group was not large enough to define the prog-
nostic value of PDCD4, and not having nucleus-specific 
PDCD4 protein measurements could also restrict the 
precise evaluation. Future studies on a larger scale are 
warranted to address the association of PDCD4 with the 
unique clinical features presented by different cancers.
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